Karin Kleinhans

Karin has over 9 years of experience in the life science industry extending across research, IP law, venture capital and private equity. She is currently a Partner at MRLV.

Prior to becoming part of the MRLV team, she was a Partner at EQT, a global purpose driven private equity firm, and part of its life sciences focused team. Prior to that, she was a Partner at LSP (now EQT Life Sciences), an Amsterdam, Munich and Boston based leading European healthcare focused investment firm with more than $3.2B under management where she focused on venture capital investments across a broad range of life science companies including: Cardior Pharmaceuticals, Arcieum Therapeutics, T-knife Therapeutics, Endotronix, Artios Pharma, Hotspot Therapeutics, Nkarta (NASDAQ: NKTX) and Amylyx (NASDAQ: AMLX). Before this, she worked in intellectual property law and was a scientist at the Max-Planck Department for Stem Cell Aging. She received her PhD from the International Graduate School in Molecular Medicine in Ulm funded by the Excellence Initiative of the German Federal and States Governments. She was awarded her Bachelor`s and Master`s Degree in Molecular Medicine where she combined medical studies with scientific research training.